[Form 4] Avidity Biosciences, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Steven George, Chief Medical Officer of Avidity Biosciences (RNA), exercised stock options and sold shares under a preexisting Rule 10b5-1 plan. On 08/22/2025 he exercised options to acquire 2,208 shares at an exercise price of $10.16 per share and simultaneously sold 2,208 shares in multiple transactions at a weighted-average sale price of $46.4047 per share, with individual sale prices ranging from $44.64 to $47.03. After these transactions he beneficially owned 41,075 shares before the sale and 38,867 shares following the sale. The option exercised was granted 01/20/2024, vests monthly in equal installments of 2,208 shares and becomes fully vested on 01/20/2028. The reporting person adopted the 10b5-1 plan on 06/12/2024.

Positive

• Transaction executed under a Rule 10b5-1 plan adopted 06/12/2024, which documents preplanned trading
• Full disclosure of exercise and sale details including exercise price, weighted-average sale price, and sale price range

Negative

• Beneficial ownership decreased from 41,075 to 38,867 shares after the transactions

Insights

Securities Analyst

TL;DR: Officer exercised options and sold the same number of shares under a 10b5-1 plan, reducing direct holdings modestly.

The filing shows a routine exercise of a previously granted option and contemporaneous sale of the acquired shares under a Rule 10b5-1 trading plan adopted 06/12/2024. The transactions were executed on 08/22/2025: 2,208 option shares were exercised at $10.16 and 2,208 shares were sold at a weighted-average price of $46.4047, with sale prices between $44.64 and $47.03. Beneficial ownership decreased from 41,075 to 38,867 shares. This appears to be an ordinary monetization of vested compensation rather than a company-specific signal, and the clear 10b5-1 attribution reduces the likelihood of informational trading.

Corporate Governance Expert

TL;DR: Disclosure is complete and cites the 10b5-1 plan; transactions are consistent with preplanned insider sales.

The Form 4 discloses material mechanics: grant date (01/20/2024), vesting schedule (monthly installments of 2,208 shares until full vesting on 01/20/2028), exercise price ($10.16) and sale price range ($44.64 to $47.03). The filer affirms the trades were effected pursuant to a 10b5-1 plan adopted 06/12/2024 and offers to provide per-price breakdowns upon request. From a governance perspective the filing meets Section 16 disclosure requirements and documents the insiders use of a structured trading plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hughes Steven George

(Last) (First) (Middle)

C/O AVIDITY BIOSCIENCES, INC.

10578 SCIENCE CENTER DRIVE, SUITE 125

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Avidity Biosciences, Inc. [ RNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/22/2025		M(1)		2,208	A	$10.16	41,075	D
Common Stock	08/22/2025		S(1)		2,208	D	$46.4047(2)	38,867	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.16	08/22/2025		M(1)			2,208	(3)	01/19/2034	Common Stock	2,208	$0	72,875	D

Explanation of Responses:

1. The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024.

2. This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.64 to $47.03. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. This option was granted on January 20, 2024 and vests in equal installments of 2,208 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2028.

Remarks:

	/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact	08/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Avidity Biosciences (RNA) insider Steven George do on 08/22/2025?

He exercised 2,208 option shares at an exercise price of $10.16 and sold 2,208 shares at a weighted-average price of $46.4047 under a 10b5-1 plan.

How did Steven Georges ownership change after the Form 4 transactions?

Beneficial ownership decreased from 41,075 shares to 38,867 shares following the reported transactions.

Were the sales part of a preplanned trading arrangement?

Yes. The exercises and sales were effected pursuant to a Rule 10b5-1 trading plan adopted on 06/12/2024.

What was the sale price range for the shares sold?

Shares were sold in multiple transactions at prices ranging from $44.64 to $47.03, with a weighted-average price of $46.4047.

When was the option granted and when does it fully vest?

The option was granted on 01/20/2024 and vests in equal monthly installments of 2,208 shares until fully vested on 01/20/2028.